We at CPP would like to extend a heartfelt thanks to all of our members and vendor partners that have made this year a banner year for CPP! It is only through collaboration with our partners and sharing information and resources among our members that we are able to maximize opportunities for in-office immunizations for all patients. Thank you for all you do to minimmize vaccine-preventable diseases in our communities!
On November 1, 2016, Pfizer announced new pricing (effective January 27, 2017) and payment terms (effective December 1, 2016) for their Prevnar 13 and Trumenba vaccines. For details and updated pricing sheets, CPP members can contact the CPP office at 614-722-2145 or firstname.lastname@example.org.
In addition, the Advisory Committee on Immunization Practices (ACIP) met in October and provided additional guidance on the updated dosing schedules for one serogroup B meningococcal vaccine, MenB-FHbp (Trumenba).
- For persons at increased risk for meningococcal disease and during serogroup B outbreaks, 3 doses of MenB-FHbp administered at 0, 1-2, and 6 months.
- When given to healthy adolescents not at increased risk for meningococcal disease, 2 doses of MenB-FHbp at 0 and 6 months.
If approved by the CDC Director, the recommendations will become official once published in MMWR.